NCT03180034View on ClinicalTrials.gov

Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

27,945

Participants

Timeline

Start Date

November 29, 2017

Primary Completion Date

August 21, 2025

Study Completion Date

August 1, 2028

Conditions
Human Papillomavirus InfectionHuman Papillomavirus-Related Cervical Carcinoma
Interventions
BIOLOGICAL

Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed

Given IM

OTHER

Questionnaire Administration

Ancillary studies

BIOLOGICAL

Recombinant Human Papillomavirus Bivalent Vaccine

Given IM

BIOLOGICAL

Recombinant Human Papillomavirus Nonavalent Vaccine

Given IM

Trial Locations (1)

50101

Agencia Costarricense de Investigaciones Biomédicas (ACIB), Liberia

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

National Cancer Institute (NCI)

NIH